Piperacillin 4g / Tazobactam 500mg powder for solution for infusion vials
NHS hospitals in England used £103,350,321 of indicative cost of Piperacillin 4g / Tazobactam 500mg powder for solution for infusion vials in the 12 months to April 2026, about 0.4% of all hospital medicines spend. That is down 5.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Piperacillin 4g / Tazobactam 500mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Piperacillin 4g / Tazobactam 500mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Univ Hpl B/Ham Nhs Foundation Trust | £3,612,361 |
| Aintree University Hospital Nhs Ft | £2,748,981 |
| Derby Teaching Hospitals Nhs Found Trust | £2,631,578 |
| Nottingham University Hospitals Trust | £2,484,276 |
| Sheffield Teaching Hospitals Nhs Trust | £2,071,559 |
| Colchester Hospital University Nhs Ft | £2,061,663 |
| Salford Royal Nhs Foundation Trust | £2,033,476 |
| Manchester University Nhs Ft | £1,837,574 |
| University Hpls North Midlands Nhs Trust | £1,761,051 |
| Royal Free London Nhs Foundation Trust | £1,742,500 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.